AI enables personalized treatment for myeloma

A multidisciplinary team of researchers has developed an artificial intelligence platform that could enable doctors to prescribe personalized treatments for myeloma patients.

A research group in Singapore has used artificial intelligence (AI) to identify optimized combinatorial drug treatments for myeloma, a type of blood cancer. Their methods and findings are published in Science Translational Medicine.

Existing methods for designing drug combinations typically involve testing arbitrary combinations of commonly used drugs or incorporating new targeted therapies into established drug combinations. Bortezomib-containing drug combinations are currently used as the first and second-line treatment for multiple myeloma. However, most patients inevitably become resistant to these drugs and new combinations need to be established. While some newer combinations have been shown to be effective for some patients, rapid identification of an optimal personalized treatment for a specific patient from an infinite span of possible drug combinations remains a challenge.

Read more: